"Sick Fat," Metabolic Disease, and Atherosclerosis

American Journal of Medicine

Volumn 122, Issue 1 SUPPL., 2009, Pages

  Bays, Harold E ^a  

^a LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

Author keywords

Abdominal obesity; Adiposopathy; Atherosclerosis; Coronary heart disease; Metabolic syndrome

Indexed keywords

APOLIPOPROTEIN C2; CANNABINOID RECEPTOR ANTAGONIST; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSIGLITAZONE; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ABDOMINAL OBESITY; ABDOMINAL SUBCUTANEOUS FAT; ADIPOSE TISSUE; ARTICLE; BODY MASS; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY RISK; DIABETIC NEPHROPATHY; DISEASE EXACERBATION; DYSLIPIDEMIA; FATTY LIVER; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTRAABDOMINAL FAT; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRITION EDUCATION; NUTRITIONAL COUNSELING; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION;

ABDOMINAL FAT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DYSLIPIDEMIAS; FOOD HABITS; HEALTH BEHAVIOR; HUMANS; HYPERTENSION; HYPERTROPHY; LIFE STYLE; RISK FACTORS;

EID: 57749093663     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2008.10.015     Document Type: Article

References (64)

1. Yusuf S., Hawken S., Ounpuu S., et al., INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364 (2004) 937-952
2. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation 106 (2002) 3143-3421
3. Bays H.E., Rodbard R.W., Schorr A.B., and González-Campoy J.M. Adiposopathy: treating pathogenic adipose tissue (adiposopathy) to reduce cardiovascular disease risk. Curr Treat Options Cardiovasc Med 9 (2007) 259-271
4. Bays H.E., Gonzalez-Campoy J.M., Henry R.R., Bergman D.A., Kitabchi A.E., Schorr A.B., Rodbard H.W., and Adiposopathy Working Group. Is adiposopathy (sick fat) an endocrine disease?. Int J Clin Pract 62 (2008) 1474-1483
5. Pladevall M., Singal B., Williams L.K., et al. A single factor underlies the metabolic syndrome: a confirmatory factor analysis. Diabetes Care 29 (2006) 113-122
6. Stern M.P. Diabetes and cardiovascular disease: the "common soil" hypothesis. Diabetes 44 (1995) 369-374
7. Bays H. Adiposopathy, metabolic syndrome, quantum physics, general relativity, chaos and the Theory of Everything. Expert Rev Cardiovasc Ther 3 (2005) 393-404
8. Bays H.E., Gonzalez-Campoy J.M., Bray G.A., et al. The pathogenic potential of adipose tissue and the metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther 6 (2008) 343-368
9. Bays H., and Ballantyne C. Adiposopathy: why do adiposity and obesity cause metabolic disease?. Future Lipidology 1 (2006) 389-420
10. O'Keefe Jr. J.H., Cordain L., Harris W.H., Moe R.M., and Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol 43 (2004) 2142-2146
11. Dierenfeld E.S., Hoppe P.P., Woodford M.H., Krilov N.P., Klimov V.V., and Yasinetskaya N.I. Plasma alpha-tocopherol, beta-carotene, and lipid levels in semi-free-ranging Przewalski horses (Equus prezewalskii). J Zoo Wildl Med 28 (1997) 144-147
12. Vitić J., and Stevanović J. Comparative studies of the serum lipoproteins and lipids in some domestic, laboratory and wild animals. Comp Biochem Physiol B 106 (1993) 223-229
13. Lochmiller R.L., and Grant W.E. Serum chemistry of the collared peccary (Tayassu tajacu). J Wildl Dis 20 (1984) 134-140
14. Ghebremeskel K., Williams G., Lewis J.C., and Du Toit R. Serum alpha-tocopherol, all-trans retinol, total lipids and cholesterol in the black rhinoceros (Diceros bicornis). Comp Biochem Physiol A 91 (1988) 343-345
15. Dillman J.S., and Car W.R. Observations on arteriosclerosis, serum cholesterol and serum electrolytes in the wild African elephant (Loxodonta africana). J Comp Pathol 80 (1970) 81-87
16. Kemnitz J.W., Sapolsky R.M., Altmann J., Muruthi P., Mott G.E., and Stefanick M.L. Effects of food availability on serum insulin and lipid concentrations in free-ranging baboons. Am J Primatol 57 (2002) 13-19
17. Vié J.C., Moreau B., de Thoisy B., Fournier P., and Genty C. Hematology and serum biochemistry values of free-ranging red howler monkeys (Alouatta seniculus) from French Guiana. J Zoo Wildl Med 29 (1998) 142-149
18. Clark S.B., Tercyak A.M., and Glander K.E. Plasma lipoproteins of free-ranging howling monkeys (Alouatta palliata). Comp Biochem Physiol B 88 (1987) 729-735
19. Malaga C.A., Weller R.E., Buschbom R.L., and Ragan H.A. Serum chemistry of the wild caught karyotype I night monkey (Aotus nancymai). Lab Anim Sci 41 (1991) 143-145
20. Barnicot N.A., Bennett F.J., Woodburn J.C., Pilkington T.R., and Antonis A. Blood pressure and serum cholesterol in the Hadza of Tanzania. Hum Biol 44 (1972) 87-116
21. Corcoran A.C., and Rabinowitch I.M. A study of the blood lipoids and blood protein in Canadian Eastern Arctic Eskimos. Biochem J 31 (1937) 343-348
22. Truswell A.S. Diet and nutrition of hunter-gatherers. Ciba Found Symp (1977) 213-221
23. Mann G.V., Roels O.A., Price D.L., and Merrill J.M. Cardiovascular disease in African Pygmies: a survey of the health status, serum lipids and diet of Pygmies in Congo. J Chronic Dis 15 (1962) 341-371
24. Wilmsen E.N. Seasonal effects of dietary intake on Kalahari San. Fed Proc 37 (1978) 65-72
25. Eberhardt M.S., Ingram D.D., and Makuc D.M. Urban and Rural Chartbook: Health in the United States, 2001 (2001), National Center for Health Statistics, Hyattsville, MD DHS Publication No. 01-1232
26. Bays H.E., Chapman R.H., and Grandy S. The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys. Int J Clin Pract 61 (2007) 737-747
27. World Health Organization. Global strategy on diet, physical activity and health. http://www.who.int/dietphysicalactivity/publications/facts/obesity/en/ Accessed January 4, 2008
28. Balkau B., Shipley M., Jarrett R.J., Pyörälä K., Pyörälä M., Forhan A., and Eschwège E. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 21 (1998) 360-367
29. Selvin E., Coresh J., Golden S.H., Brancati F.L., Folsom A.R., and Steffes M.W. Glycemic control and coronary heart disease risk in persons with and without diabetes: the Atherosclerosis Risk in Communities study. Arch Intern Med 165 (2005) 1910-1916
30. Lehto S., Ronnemaa T., Pyorala K., and Laakso M. Poor glycemic control predicts coronary heart disease events in patients with type 1 diabetes without nephropathy. Arterioscler Thromb Vasc Biol 19 (1999) 1014-1019
31. Howard B.V., Best L.G., Galloway J.M., et al. Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. Diabetes Care 29 (2006) 391-397
32. Nathan D.M., Cleary P.A., Backlund J.Y., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353 (2005) 2643-2653
33. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998) 854-865
34. Erdmann E., Dormandy J.A., Charbonnel B., Massi-Benedetti M., Moules I.K., Skene A.M., and PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 49 (2007) 1772-1780
35. National Heart, Lung, and Blood Institute. For safety, NHLBI changes intensive blood sugar treatment strategy in clinical trial of diabetes and cardiovascular disease [news release on ACCORD Trial]. February 6, 2008. http://public.nhlbi.nih.gov/newsroom/home/GetPressRelease.aspx?id=2551 Accessed February 14, 2008
36. Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) trial Web site. Major international diabetes study does not confirm increased risk of death reported by US trial: preliminary findings from the largest-ever study of treatments for diabetes provide no evidence that intensive treatment to lower blood glucose (sugar) increases risk of death [news release]. February 13, 2008. http://www.advance-trial.com/static/html/virtual/contents.asp?P=39 Accessed March 13, 2008
37. Lewington S., Clarke R., Qizilbash N., Peto R., Collins R., et al., Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360 (2002) 1903-1913
38. Vasan R.S., Larson M.G., Leip E.P., Evans J.C., O'Donnell C.J., Kannel W.B., and Levy D. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 345 (2001) 1291-1297
39. National High Blood Pressure Education Program JNC 7 Express. The Seventh Report of the Joint National Committee on Prevention, Evaluation, and Treatment of High Blood Pressure. www.nhlbi.nih.gov/guidelines/hypertension/express.pdf Accessed January 4, 2008
40. Bays H.E., and McGovern M.E. Time as a variable with niacin extended-release/lovastatin vs. atorvastatin and simvastatin. Prev Cardiol 8 (2005) 226-233
41. Bays H., McKenney J., and Davidson M. Torcetrapib/atorvastatin combination therapy. Expert Rev Cardiovasc Ther 3 (2005) 789-820
42. Schaefer E.J., and Asztalos B.F. Increasing high-density lipoprotein cholesterol, inhibition of cholesteryl ester transfer protein, and heart disease risk reduction. Am J Cardiol 100 suppl 1 (2007) S25-S31
43. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
44. American Diabetes Association. Executive summary: standards of medical care in diabetes-2008. Diabetes Care 31 (2008) S5-S11. http://care.diabetesjournals.org/cgi/reprint/31/Supplement_1/S5 Available at: http://care.diabetesjournals.org/cgi/reprint/31/Supplement_1/S5. Accessed April 8, 2008
45. Grundy S.M., Cleeman J.I., Daniels S.R., et al., American Heart Association and the National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 112 (2005) 2735-2752
46. Kahn R., Buse J., Ferrannini E., and Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28 (2005) 2289-2304
47. Karelis A.D., St-Pierre D.H., Conus F., Rabasa-Lhoret R., and Poehlman E.T. Metabolic and body composition factors in subgroups of obesity: what do we know?. J Clin Endocrinol Metab 89 (2004) 2569-2575
48. Bays H., Abate N., and Chandalia M. Adiposopathy: sick fat causes high blood sugar, high blood pressure, and dyslipidemia. Future Cardiology 1 (2005) 39-59
49. Bays H., Blonde L., and Rosenson R. Adiposopathy: how do diet, exercise, weight loss and drug therapies improve metabolic disease?. Expert Rev Cardiovasc Ther 4 (2006) 871-895
50. Gavrilova O., Marcus-Samuels B., Graham D., et al. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest 105 (2000) 271-278
51. Bays H., Mandarino L., and DeFronzo R.A. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 89 (2004) 463-478
52. Oreopoulos A., Padwal R., Norris C.M., Mullen J.C., Pretorius V., and Kalantar-Zadeh K. Effect of obesity on short- and long-term mortality postcoronary revascularization: a meta-analysis. Obesity 16 (2008) 442-450
53. Kushner R.F., and Roth J.L. Assessment of the obese patient. Endocrinol Metab Clin North Am 32 (2003) 915-933
54. Higuchi M.L., Gutierrez P.S., Bezerra H.G., et al. Comparison between adventitial and intimal inflammation of ruptured and nonruptured atherosclerotic plaques in human coronary arteries. Arq Bras Cardiol 79 (2002) 20-24
55. Storlien L., Oakes N.D., and Kelley D.E. Metabolic flexibility. Proc Nutr Soc 63 (2004) 363-368
56. Adams II J.M., Pratipanawatr T., Berria R., Wang E., DeFronzo R.A., Sullards M.C., and Mandarino L.J. Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes 53 (2004) 25-31
57. Chavez J.A., Holland W.L., Bär J., Sandhoff K., and Summers S.A. Acid ceramidase overexpression prevents the inhibitory effects of saturated fatty acids on insulin signaling. J Biol Chem 280 (2005) 20148-20153
58. Kelley D.E., and Goodpaster B.H. Skeletal muscle triglyceride: an aspect of regional adiposity and insulin resistance. Diabetes Care 24 (2001) 933-941
59. Kelley D.E., and Mandarino L.J. Fuel selection in human skeletal muscle in insulin resistance: a reexamination. Diabetes 49 (2000) 677-683
60. Grill V., Persson G., Carlsson S., et al. Family history of diabetes in middle-aged Swedish men is a gender unrelated factor which associates with insulinopenia in newly diagnosed diabetic subjects. Diabetologia 42 (1999) 15-23
61. Higuchi M.L., Gutierrez P.S., Bezerra H.G., et al. Comparison between adventitial and intimal inflammation of ruptured and nonruptured atherosclerotic plaques in human coronary arteries. Arq Bras Cardiol 79 (2002) 20-24
62. Bays H. Adiposopathy: the endocannabinoid system as a therapeutic treatment target for dysfunctional "sick" fat. California Journal of Health System Pharmacy 19 (2007) 32-39
63. Bays H. The melanocortin system as a therapeutic treatment target for adiposity and adiposopathy. Drugs R D 7 (2006) 289-302
64. Rubino F., Forgione A., Cummings D.E., et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg 244 (2006) 741-749